Skip to main content
OpenTrials
Completed

NCT Number: NCT02563197

Inhalation Flow Rate-study

Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Gauting, Bavaria, Germany

Loading trial locations.

About this study

The aim of the study is to measure inspiratory profiles of patients with non-Cystic fibrosis bronchiectasis using the breath activated T-326 Inhaler.

The following parameters will be derived from the inspiratory profiles:

  • Peak Inspiratory Flow (PIF, in L/min)
  • Inspiratory Volume (V, in L)
  • Inspiratory Time (t, in s).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)
  • Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory Society criteria
  • Clinically stable in the opinion of the investigator at the time of the study visit.
  • Male and female patients ≥ 18 years of age.

Exclusion criteria

  • Pulmonary exacerbation (as judged by the investigator, based on the clinical condition of the subject and taking into account e.g., febrile infection of the lung, relevant decrease in Forced expiratory volume in the first second (FEV1) value, increased sputum production, sputum purulence, recent hospitalization) at study visit or within the preceding six (6) weeks.
  • History of lung transplant.
  • Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the preceding six (6) weeks before screening.
  • Established diagnosis of bronchial asthma.
  • Established diagnosis of cystic fibrosis.
  • Proof of any relevant medical finding or disease in the last three (3) months which might interfere with participation in the study or patient safety (e.g. pneumothorax, uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction, cerebral vascular accident).
  • A relevant disease that is considered to interfere with the study results is any disease that, except for the impairment of lung function, interferes with the patient's ability to inhale from the device. For example, COPD per se is usually not considered as a reason for patient exclusion, unless coughing or obliteration of the upper airways with sputum interferes with the patient's ability to inhale from the device.
  • Relevant surgical history in the last 3 months (e.g., but not limited to abdominal, thoracic, ocular or brain surgery).
  • History or evidence of lung resection, thoracotomy, known aneurysm and severe scoliosis.
  • Pregnancy.

Treatment and study plan

T-326 Inhaler

Device

No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.

Primary outcomes

  1. Peak inspiratory flow (L/min)

    Time frame: Visit 2 (1-14 days after screening visit 1)

Secondary outcomes

  1. Inspiratory volumes (V in L)

    Time frame: Visit 2 (1-14 days after screening visit 1)

  2. Inspiratory time (t in s)

    Time frame: Visit 2 (1-14 days after screening visit 1)

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Collaborators

  • Novartis

Registry information

Official study title

An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Sep 30, 2015
Registry last updated
Apr 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.